Consultation on Amendments to the Agreed 2021 ABPI Code

Following agreement of the 2021 Code, there is a need to make two amendments. Please submit any comments as soon as possible and by no later than Thursday 1 April 2021.

Further information - Click here

The Prescription Medicines Code of Practice Authority

The Prescription Medicines Code of Practice Authority (PMCPA) is the self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, independently of the ABPI.  It was established by the ABPI on 1 January 1993.

The Authority is responsible for the provision of advice, guidance and training on the Code as well as for the complaints procedure.  It is also responsible for arranging for conciliation between companies when requested to do so and for arranging for the scrutiny of advertising and meetings on a regular basis.

 

TRAINING 

Code of Practice Seminars 

- dates under review. Due to government guidance on COVID-19 the PMCPA has cancelled the Seminar previously scheduled for June 2020 and further dates are subject to change.

ABPI Examination for Medical Representatives

postponed due to COVID-19. More information is available on the ABPI website, link below

https://exams.abpi.org.uk/Pages/home.aspx

To extend the time available to take the examination an application for an extension should be made on the form on this website, link below  

https://www.pmcpa.org.uk/training/application-for-an-extension-of-time-to-take-the-representative-examinations/

The extension request should preferably be made by the company rather than the representative. 

In house training 

- under review due to COVID-19

eLearning Module 

- unavailable until after the next version of the ABPI Code has been agreed and implemented

For more information see Training Opportunities. 

https://www.pmcpa.org.uk/training/

Media

  • Consultation on Amendments to the Agreed 2021 ABPI Code

    24 March 2021

    read more
  • Camurus, Accord, Swedish Orphan Biovitrum (Sobi), Strides Pharma, Boehringer Ingelheim, Vifor Pharma, GlaxoSmithKline and Sintetica named in advertisements for breaches of the ABPI Code

    02 March 2021

    read more